Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female participants ≥18 years old.~2. Participants with Stage V chronic kidney disease who received a kidney transplant from a deceased donor to whom they were sensitized.~3. History of prior exposure to HLA (human leukocyte antigen):~   * Prior solid organ or tissue allograft~  * Pregnancy~  * Blood transfusion~  * Prior exposure to specific donor's HLA~Exclusion Criteria:~1. Has received treatment with eculizumab at any time prior to enrolling in this study.~2. Blood type (A, B, and O blood glycoproteins-blood type) incompatible with deceased donor.~3. History of severe cardiac disease.~4. Prior splenectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).